טוען...
Development of tumor lysis syndrome (TLS): A potential risk factor in cancer patients receiving anticancer therapy
Tumor lysis syndrome (TLS) is characterized by hyperuricaemia, hyperphosphatemia, hyperkalaemia, as well as hypocalcaemia due to the breakdown of tumor cells undergoing cancer therapy (chemo/radio). Therefore it is of interest to evaluate oxidative stress using selective biological markers [Malondia...
שמור ב:
| הוצא לאור ב: | Bioinformation |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Biomedical Informatics
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4261116/ https://ncbi.nlm.nih.gov/pubmed/25512688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6026/97320630010703 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|